Literature DB >> 34072949

Prognostic Implications of MRI Melanin Quantification and Cytogenetic Abnormalities in Liver Metastases of Uveal Melanoma.

Toulsie Ramtohul1, Khadija Ait Rais2, Sophie Gardrat3, Raymond Barnhill4, Sergio Román-Román4, Nathalie Cassoux5, Manuel Rodrigues6, Pascale Mariani5, Leanne De Koning4, Gaëlle Pierron2, Vincent Servois1.   

Abstract

To evaluate the prognostic implications of melanin quantification assessed by magnetic resonance imaging (MRI) with respect to the clinical, pathological, and genetic features of liver metastases of uveal melanoma (LMUM). This single-center retrospective cohort study included 63 patients eligible for margin-free resection of LMUM between 2007 and 2018. Comparative genomic hybridization of resected liver metastases on microarrays was performed for genetic risk classification. Metastases exhibiting monosomy 3 with any type of gain of chromosome 8 (M3/8g) were considered high-genetic-risk. MRI melanin quantification using the mean T1 signal (mT1s) in liver metastases was assessed quantitatively on preoperative imaging examination and compared to that of gross pathological evaluation. The association between MRI melanin quantification and overall survival (OS) was assessed by multivariate analysis using the Cox proportional hazards model. Gross pathological assessment of melanin content and MRI melanin quantification were strongly correlated (r = 0.8, p < 0.001). Independent prognostic factors associated with OS were disease-free interval ≤ 24 months (HR = 3.1; 95% CI, 1.6-6.0; p < 0.001), high-genetic-risk (HR = 2.2; 95% CI, 1.1-4.8; p = 0.04), mT1s > 1.1 (HR = 2.3; 95% CI, 1.2-4.7; p = 0.019), and complete hepatic resection (HR = 0.3; 95% CI, 0.2-0.7; p = 0.004). In patients with high-genetic-risk, mT1s showed a significant association with OS (HR = 3.7; 95% CI, 1.5-9.3; p = 0.006). The median OS was 17.5 months vs. 27 months for >1.1 and ≤1.1 mT1s tumors, respectively (p = 0.003). We showed that the level of pigmentation in M3/8g LMUM identified two subsets that were correlated with distinct clinical outcomes.

Entities:  

Keywords:  genetic classification; melanin quantification; metastatic uveal melanoma; prognosis

Year:  2021        PMID: 34072949     DOI: 10.3390/cancers13112728

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  29 in total

1.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  Lancet       Date:  2007-10-20       Impact factor: 79.321

2.  Detection of M2-macrophages in uveal melanoma and relation with survival.

Authors:  Inge H G Bronkhorst; Long V Ly; Ekaterina S Jordanova; Johannes Vrolijk; Mieke Versluis; Gregorius P M Luyten; Martine J Jager
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-02-03       Impact factor: 4.799

3.  Surgical management of liver metastases from uveal melanoma: 16 years' experience at the Institut Curie.

Authors:  P Mariani; S Piperno-Neumann; V Servois; M G Berry; T Dorval; C Plancher; J Couturier; C Levy-Gabriel; L Lumbroso-Le Rouic; L Desjardins; R J Salmon
Journal:  Eur J Surg Oncol       Date:  2009-03-28       Impact factor: 4.424

Review 4.  Prognosis of uveal melanoma based on race in 8100 patients: The 2015 Doyne Lecture.

Authors:  C L Shields; S Kaliki; M N Cohen; P W Shields; M Furuta; J A Shields
Journal:  Eye (Lond)       Date:  2015-08-07       Impact factor: 3.775

5.  Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases.

Authors:  Julien Trolet; Philippe Hupé; Isabelle Huon; Ingrid Lebigot; Charles Decraene; Olivier Delattre; Xavier Sastre-Garau; Simon Saule; Jean-Paul Thiéry; Corine Plancher; Bernard Asselain; Laurence Desjardins; Pascale Mariani; Sophie Piperno-Neumann; Emmanuel Barillot; Jérôme Couturier
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-01-17       Impact factor: 4.799

6.  Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma.

Authors:  A Gordon Robertson; Juliann Shih; Christina Yau; Ewan A Gibb; Junna Oba; Karen L Mungall; Julian M Hess; Vladislav Uzunangelov; Vonn Walter; Ludmila Danilova; Tara M Lichtenberg; Melanie Kucherlapati; Patrick K Kimes; Ming Tang; Alexander Penson; Ozgun Babur; Rehan Akbani; Christopher A Bristow; Katherine A Hoadley; Lisa Iype; Matthew T Chang; Andrew D Cherniack; Christopher Benz; Gordon B Mills; Roel G W Verhaak; Klaus G Griewank; Ina Felau; Jean C Zenklusen; Jeffrey E Gershenwald; Lynn Schoenfield; Alexander J Lazar; Mohamed H Abdel-Rahman; Sergio Roman-Roman; Marc-Henri Stern; Colleen M Cebulla; Michelle D Williams; Martine J Jager; Sarah E Coupland; Bita Esmaeli; Cyriac Kandoth; Scott E Woodman
Journal:  Cancer Cell       Date:  2017-08-14       Impact factor: 31.743

7.  Melanin content in melanoma metastases affects the outcome of radiotherapy.

Authors:  Anna A Brożyna; Wojciech Jóźwicki; Krzysztof Roszkowski; Jan Filipiak; Andrzej T Slominski
Journal:  Oncotarget       Date:  2016-04-05

8.  Comprehensive analysis of cutaneous and uveal melanoma liver metastases.

Authors:  Esmee P Hoefsmit; Elisa A Rozeman; Trieu My Van; Petros Dimitriadis; Oscar Krijgsman; Jordan W Conway; Ines Pires da Silva; Jacqueline E van der Wal; Steven L C Ketelaars; Kaspar Bresser; Annegien Broeks; Ron M Kerkhoven; Jason W Reeves; Sarah Warren; Pia Kvistborg; Richard A Scolyer; Ellen W Kapiteijn; Daniel S Peeper; Georgina V Long; Ton N M Schumacher; Christian U Blank
Journal:  J Immunother Cancer       Date:  2020-12       Impact factor: 13.751

9.  Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis.

Authors:  Elina S Rantala; Micaela Hernberg; Tero T Kivelä
Journal:  Melanoma Res       Date:  2019-12       Impact factor: 3.599

View more
  3 in total

1.  Tumour growth rate improves tumour assessment and first-line systemic treatment decision-making for immunotherapy in patients with liver metastatic uveal melanoma.

Authors:  Toulsie Ramtohul; Axel Cohen; Manuel Rodrigues; Sophie Piperno-Neumann; Luc Cabel; Nathalie Cassoux; Livia Lumbroso-Le Rouic; Denis Malaise; Sophie Gardrat; Gaëlle Pierron; Pascale Mariani; Vincent Servois
Journal:  Br J Cancer       Date:  2022-03-26       Impact factor: 9.075

2.  Amelanotic Uveal Melanomas Evaluated by Indirect Ophthalmoscopy Reveal Better Long-Term Prognosis Than Pigmented Primary Tumours-A Single Centre Experience.

Authors:  Anna Markiewicz; Piotr Donizy; Monika Nowak; Mateusz Krzyziński; Martyna Elas; Przemysław M Płonka; Jolanta Orłowska-Heitzmann; Przemysław Biecek; Mai P Hoang; Bożena Romanowska-Dixon
Journal:  Cancers (Basel)       Date:  2022-06-01       Impact factor: 6.575

3.  Label-Free Delineation of Human Uveal Melanoma Infiltration With Pump-Probe Microscopy.

Authors:  Bohan Zhang; Tengteng Yao; Yaxin Chen; Chuqiao Wang; Yongyang Bao; Zhaoyang Wang; Keke Zhao; Minbiao Ji
Journal:  Front Oncol       Date:  2022-07-22       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.